Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 21, 2012

Primary Completion Date

November 3, 2014

Study Completion Date

July 3, 2019

Conditions
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Interventions
BIOLOGICAL

Ipilimumab

Trial Locations (17)

10065

Memorial Sloan Kettering Nassau, New York

10461

Montefiore Medical Center, The Bronx

15213

Magee-Womens Hospital Of Upmc, Pittsburgh

27710

Duke University Medical Center, Durham

28204

The Charlotte-Mecklenburg Hospital Authority, Charlotte

30308

Winship Cancer Institute., Atlanta

32804

AdventHealth Cancer Institute, Orlando

33612

H. Lee Moffitt Cancer Center, Tampa

44109

MetroHealth Medical Center, Cleveland

46202

Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis

60521

Dr. Sudarshan K. Sharma, Ltd., Hinsdale

70433

Women'S Cancer Care, Covington

73104

Peggy and Charles Stephenson Cancer Center, Oklahoma City

74146

Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa

06520

Yale University School Of Medicine, New Haven

30912-3335

Georgia Regents University, Augusta

02215

Dana Farber Cancer Institute., Boston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY